Priorclave partner Virginia Tech is pursuing new therapies to treat people with gliobastomas at its Carilion Research Institute<\/a>. Michael J. Friedlander, founding executive director of the institute and vice president for health sciences and technology at Virginia Tech, said that although other forms of cancer are more common, their scientists chose to work on glioblastomas because there was a lack of effective therapies to deal with this aggressive cancer.<\/p>\nAn interdisciplinary research team\u2014bringing together engineering, neuroscience, and biomedical science\u2014are working on several different therapies, including a pioneering personalized cancer medicine that uses a patient\u2019s own cancer stem cells to target the glioblastoma.<\/p>\n